Home/Jasper Therapeutics/William D. (Bill) Lis
WD

William D. (Bill) Lis

Chief Executive Officer and Board Member

Jasper Therapeutics

Jasper Therapeutics Pipeline

DrugIndicationPhase
Briquilimab (JSP191)Conditioning for allogeneic hematopoietic cell transplant in Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)Phase 1/2